From the United States comes the hope that African populations can be almost fully immunised by next year.
The Washington government and partners in the campaign have announced a loan of $770 million to solve the problem of acquiring and distributing doses on the continent once and for all.
It will simply invest in the production of vaccines locally and in the implementation of laboratories that can then be useful in the future.
The project will revolve around South Africa, which will be the base and main production centre.
Like the Mediterranean belt of the continent and a few other countries, South Africa is fighting against the third wave of the virus and the Delta variant, which seems to have more effect on its citizens and the various ethnic groups scattered across Africa.
The US International Development Finance Corporation (DFC) announced on Thursday that the money will be given to South African holding company Aspen Pharmacare H, with the idea of expanding the region's vaccine production capacity. 
"We are fulfilling President Biden's promise," said David Marchik, DFC's chief operating officer, "and we aim to do everything we can to increase local production. Our goal is to help Africans develop production in Africa for Africa. The direct loan to South Africa will help Aspen's effort to produce vaccines for all by 2021 and 2022, thus helping to achieve the African Union's (AU) target of vaccinating 400 million people." Germany and France, through their financial institutions, are expected to join the loan.
Aspen will be in charge of producing the Covid-19 vaccines in close contact with the World Health Organisation (WHO). Initially, it will produce the Johnson & Johnson vaccine.
Ninety-two countries have signed up to the Covax programme, and they will be given priority for distribution, taking into account the most serious situations that currently affect the country chosen for production. Part of the funding will go to support vaccine storage facilities and distribution logistics.
(photo: Getty Images)